Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2019-09-20 AGM Information
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Uitnodiging voor de bijzondere en buitengewone algemene vergaderingen
AGM Information Classification · 98% confidence The document is an official invitation to shareholders for a special and extraordinary general meeting (EGM/SGM) of Galapagos NV. It outlines the agenda items, such as the appointment of directors and the issuance of warrants, and provides instructions for attendance. While it mentions the meeting, it functions as the formal notice and proxy-related solicitation material for shareholders to participate in the upcoming meeting. Given the specific nature of soliciting votes and providing meeting details, it aligns best with Proxy Solicitation & Information Statement (PSI).
2019-09-20 Dutch
Invitation to the special and extraordinary shareholders' meetings
AGM Information Classification · 98% confidence The document explicitly invites shareholders to a 'special and extraordinary shareholders' meeting' scheduled for October 22, 2019. It details agenda items such as director appointments and capital renewal, and mentions that convening notices and related documents can be consulted on the website. This content directly relates to the materials and announcements surrounding an Annual General Meeting (AGM) or an Extraordinary General Meeting (EGM). Since the document is an invitation/announcement for the meeting itself, and not the voting results (DVA) or the formal proxy materials (PSI), the most appropriate classification is AGM-R (AGM Information/Materials). The document length is relatively short (3699 chars), but its primary function is to convene the meeting and describe its purpose, fitting the AGM-R definition better than a generic RPA or RNS.
2019-09-20 English
3. Attendance Notification Form EN & NL.pdf
AGM Information Classification · 95% confidence The document is titled 'Notification of participation' and explicitly details the process for registered shareholders and warrant holders to notify the company (Galapagos NV) of their intention to participate in upcoming 'special and extraordinary shareholders' meetings' scheduled for October 22, 2019. This document is a formal administrative notice related to attending a general meeting, not the meeting materials themselves (AGM-R) or the results (DVA). It is a prerequisite document for participation, which aligns best with materials distributed in preparation for a general meeting, often covered under Proxy Solicitation & Information Statement (PSI) or general AGM preparation materials. Given the options, 'AGM-R' (AGM Information) is the closest fit as it relates directly to the Annual General Meeting process, even though this specific form is a 'Notification of Participation' rather than the presentation itself. However, since it is a formal notice directly tied to the mechanics of attending the AGM, AGM-R is the most appropriate category among the choices provided for shareholder meeting logistics.
2019-09-20 Dutch
1. Convening Notice NL.pdf
AGM Information Classification · 98% confidence The document is explicitly titled "Uitnodiging voor de Algemene Vergaderingen van 22 oktober 2019" (Invitation to the General Meetings of October 22, 2019). It details the agenda and proposed resolutions for both a 'Bijzondere Algemene Vergadering' (Special General Meeting) and a 'Buitengewone Algemene Vergadering' (Extraordinary General Meeting). The content focuses on shareholder votes regarding board appointments and a significant capital transaction involving warrants issued to Gilead Therapeutics. This structure and content are characteristic of materials distributed to shareholders in preparation for a general meeting, which falls under the definition of AGM Information (AGM-R) or potentially Proxy Solicitation (PSI). Since the document is an explicit invitation detailing the agenda and resolutions for the meeting itself, AGM-R is the most precise classification, as it covers presentations and materials shared during the AGM context, even if it's the invitation leading up to it.
2019-09-20 Dutch
6. Special Board report 583-596-598 NL.pdf
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "Bijzonder verslag van de Raad van Bestuur overeenkomstig Artikelen 583, 596 en 598 van het Wetboek van Vennootschappen" (Special report of the Board of Directors pursuant to Articles 583, 596 and 598 of the Companies Code). It details a proposed issuance of warrants to Gilead Therapeutics and the necessary waiver of existing shareholders' pre-emptive rights, which requires shareholder approval at an Extraordinary General Meeting (BAV). This document serves as a detailed explanatory report prepared by the Board of Directors to justify a significant corporate action (issuance of capital/warrants) that requires shareholder consent, which aligns perfectly with the purpose of a special report mandated by corporate law for major transactions, often presented alongside proxy materials or as a standalone disclosure. It is not a standard Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). Given its legalistic nature, detailed explanation of a capital structure change (warrants issuance), and reference to specific articles of the Belgian Companies Code, it is best classified as a specific type of corporate disclosure related to capital/financing, but the structure strongly suggests a formal report accompanying a shareholder vote. Considering the options, while it relates to 'Capital/Financing Update' (CAP), the document's format is a formal, legally required 'Special Report' detailing the rationale for a transaction that will be voted upon at a general meeting. In many jurisdictions, such detailed reports justifying capital changes or related party transactions are often filed as part of the broader regulatory disclosure framework. Since it is a detailed report explaining a major corporate action requiring shareholder approval (which often involves proxy materials), and it is not a standard financial report (like 10-K or IR), it fits best under a category that captures formal, detailed corporate governance/transaction reports. However, since the core subject is the proposed issuance of warrants and capital increase, 'CAP' (Capital/Financing Update) is highly relevant. Given the context of Belgian corporate law requiring a 'Special Report' for waiving pre-emptive rights, this is a mandatory disclosure document. If we look closely at the content: it details the proposed issuance of warrants and the waiver of pre-emptive rights, which is a capital/financing activity. It is a comprehensive report, not just an announcement of a report (ruling 2 does not apply). Therefore, 'CAP' (Capital/Financing Update) is the most accurate fit for the subject matter, even though it is structured as a legal report. Revisiting the definitions: 'CAP' is for 'Updates on company fundraising, financing activities, or capital structure changes.' This document is the primary disclosure detailing the terms of a major financing/capital structure change (warrant issuance). I will classify it as CAP.
2019-09-20 Dutch
7. Auditor's report NL.pdf
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled 'Verslag van de commissaris aan de raad van bestuur van Galapagos NV in het kader van artikelen 596 en 598 van het Wetboek van vennootschappen' (Report of the commissioner to the board of directors of Galapagos NV under articles 596 and 598 of the Companies Code). It discusses the investigation of a special report concerning the lifting of pre-emptive rights ('voorkeurrecht') for the issuance of warrants to a specific party (Gilead). This document is a formal report by an external auditor/commissioner regarding a proposed capital action (warrant issuance involving pre-emptive right cancellation), which falls under the scope of regulatory reporting related to capital structure changes or specific audit/review opinions on such transactions. Given the focus on the auditor's opinion on financial data related to a capital increase/warrant issuance, it is most closely related to capital/financing activities, but the document itself is a formal, standalone report/opinion from the commissioner, not the primary financing announcement or the full annual report. It is a specific type of Audit Report/Information related to a corporate action. Since it is a formal report detailing the auditor's findings on the fairness of financial data related to a capital transaction (warrant issuance with pre-emptive right waiver), 'Audit Report / Information' (AR) is the most appropriate classification, as it is a standalone report providing assurance on financial aspects of a transaction, distinct from a general financing announcement (CAP) or a full annual report (10-K).
2019-09-20 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.